Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Progressive external ophthalmoplegia-myopathy-emaciation syndrome is a rare mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies characterized by progressive external ophthalmoplegia without diplopia, cerebellar atrophy, proximal skeletal muscle weakness with generalized muscle wasting, profound emaciation, respiratory failure, spinal deformity and facial muscle weakness (manifesting with ptosis, dysphonia, dysphagia and nasal speech). Intellectual disability, gastrointestinal symptoms (e.g. nausea, abdominal fullness, and loss of appetite), dilated cardiomyopathy and renal colic have also been reported.
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 9:43 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Features include always present findings: Multiple mitochondrial DNA deletions and Decreased activity of mitochondrial complex I; and very common findings: Progressive external ophthalmoplegia. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Spinal rigidity, Intellectual disability, Exercise intolerance |
Muscles | 5 | Shrinkage of the cerebellum (cerebellar atrophy), Ragged-red muscle fibers, Myopathy |
Digestive system | 4 | Nausea, Chronic diarrhea, Difficulty swallowing (dysphagia) |
Lungs and breathing | 4 | Dyspnea, Difficulty breathing (respiratory insufficiency), Respiratory failure |
Lab test results | 3 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Decreased activity of mitochondrial complex I, Decreased activity of mitochondrial complex IV |
Head and neck | 3 | Facial palsy, Microcephaly, Weakness of facial musculature |
Heart and blood vessels | 2 | Arrhythmia, Enlarged and weakened heart (dilated cardiomyopathy) |
Hormones | 1 | Hypergonadotropic hypogonadism |
Blood and immune system | 1 | Recurrent infections |
Bones and joints | 1 | Excessive outward curvature of the upper spine (kyphosis) |
Eyes | 1 | Ptosis |
Kidneys and urinary system | 1 | Nephrolithiasis |
MGME1 encodes mitochondrial genome maintenance exonuclease 1 (344 aa). Metal-dependent single-stranded DNA (ssDNA) exonuclease involved in mitochondrial genome maintenance. Highest expression in Skin Not Sun Exposed Suprapubic (42.5 TPM) and Skin Sun Exposed Lower leg (41.2 TPM).
Mitochondrial DNA depletion syndrome 11 is associated with mutations in the MGME1 gene on chromosome 20.
The MGME1 protein participates in Strand-asynchronous mitochondrial DNA replication pathway.
MGME1 is classified as a druggable target with score 0.0.
Genetic testing for MGME1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for mitochondrial DNA depletion syndrome 11 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 1 very common feature, 24 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for mitochondrial DNA depletion syndrome 11.
141 publications have been identified in PubMed for mitochondrial DNA depletion syndrome 11. Research spans Review / Meta-Analysis (56%), Basic Science / Preclinical (20%), and Case Report / Case Series (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 79 | 56% |
Laboratory research | 28 | 20% |
Patient case studies | 11 | 8% |
Disease patterns and progression | 8 | 6% |
Testing and diagnosis research | 5 | 4% |
Clinical study results | 5 | 4% |
New treatment approaches | 3 | 2% |
Other research | 2 | 1% |
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Lee S (2026). [PMID: 41206258](https://pubmed.ncbi.nlm.nih.gov/41206258/). *Am J Geriatr Psychiatry*. [Review / Meta-Analysis]
Radio FC (2026). [PMID: 41904678](https://pubmed.ncbi.nlm.nih.gov/41904678/). *Genet Med*. [Other]
Buel KL (2026). [PMID: 41569909](https://pubmed.ncbi.nlm.nih.gov/41569909/). *FP Essent*. [Review / Meta-Analysis]
Ferri C (2026). [PMID: 41798958](https://pubmed.ncbi.nlm.nih.gov/41798958/). *Front Immunol*. [Review / Meta-Analysis]
Sebode M (2026). [PMID: 41432137](https://pubmed.ncbi.nlm.nih.gov/41432137/). *Current opinion in gastroenterology*. [Review / Meta-Analysis]
Acikgoz NB (2026). [PMID: 41508548](https://pubmed.ncbi.nlm.nih.gov/41508548/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. [Gene Therapy / Novel Therapeutics]
Calafat M (2025). [PMID: 40081635](https://pubmed.ncbi.nlm.nih.gov/40081635/). *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. [Review / Meta-Analysis]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Developmental medicine and child neurology*. [Diagnostic / Biomarker]